Loading data for CCCC — first visit, this takes a few seconds.

알림

C4 Therapeutics Inc. (CCCC)

NasdaqGS: CCCC · 실시간 가격 · USD

4.18

-0.08 (-1.88%)

종가 기준: Aug 18, 2026, 8:00 PM

-1.88% (1D)

데이터 없음

매수호가	n/a
시가총액	514.25M
매출 (ttm)	35.04M
순이익 (ttm)	-101.42M
베타	2.95
EPS (ttm)	-0.91
P/E (ttm)	n/a
선행 P/E	-4.19
P/B (ttm)	2.08
P/S (ttm)	14.68
Earnings Date	Nov 5, 2026

매도호가	n/a
거래량	2,878,400
평균 거래량 (20일)	3,062,358
시가	4.21
전일 종가	4.26
일중 범위	4.11 - 4.30
52주 범위	1.69 - 5.17
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

CCCC 소개

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Oct 2, 2020

직원 수 104

상장 거래소 NasdaqGS

티커 CCCC

웹사이트 https://www.c4therapeutics.com

전체 기업 정보

재무 실적

2025년 C4 Therapeutics의 매출은 35.95M로, 전년 35.58M 대비 1.02% 증가했습니다. 순이익은 -104.99M로, -0.31% 감소했습니다.

재무제표

어닝 서프라이즈

C4 Therapeutics가 Aug 11, 2026에 분기 실적을 발표했습니다:

매출 $6.15M 예상치 하회 $0, 및 -15.00% 전년 대비 감소.

EPS -0.18 예상치 상회 0.05, 및 51.35% 전년 대비 성장.

다음 실적 발표

C4 Therapeutics Inc.의 실적 발표 예정일은 Nov 5, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Zacks

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +21.74% and +10.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1개월 전 · Zacks

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.

1개월 전 · Zacks

C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.

1개월 전 · Insider Monkey

C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?

C4 Therapeutics, Inc. (NASDAQ:CCCC) has gained roughly 16% over the past month, mainly driven by positive phase 1 clinical trial data for Cemsidomide. The data was presented on June 11, following whic...

2개월 전 · Zacks

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.

2 페이지 중 1

C4 Therapeutics Inc. (CCCC)